'Stage iiia' diaporamas de présentation

Role of Induction and Adjuvant Therapy in Regionally Advanced / Resectable NSCLC

Role of Induction and Adjuvant Therapy in Regionally Advanced / Resectable NSCLC. Rodney J. Landreneau M.D. Professor of Surgery Department of CardioThoracic Surgery University of Pittsburgh Medical Center Pittsburgh, Pennsylvania. Stage IIIA Non Small Cell Lung Cancer.

1.37k views • 104 slides

Role of Induction and Adjuvant Therapy in Regionally Advanced / Resectable NSCLC

Role of Induction and Adjuvant Therapy in Regionally Advanced / Resectable NSCLC. Rodney J. Landreneau M.D. Professor of Surgery Department of CardioThoracic Surgery University of Pittsburgh Medical Center Pittsburgh, Pennsylvania. Stage IIIA Non Small Cell Lung Cancer.

1.31k views • 104 slides

ASSESSING THE REAL RISK IN COMPLEX DISEASES

ASSESSING THE REAL RISK IN COMPLEX DISEASES. Michael N. Liebman, PhD Chief Scientific Officer Windber Research Institute. Overview. Data, Information and Knowledge Systems Biology Defining Translational Research Understanding the Question(s) Clinical Breast Care Project (CBCP)

722 views • 62 slides

Lung Neoplasms

561 views • 38 slides

Role of Surgery in Combined Treatment at Stage III

Role of Surgery in Combined Treatment at Stage III. Asso.Prof.Hasan F.Bat?rel. Stage III disease Role of surgery in Stage III NSCLC Results of studies Current problems and solutions Conclusion. Stage III Disease. Stage III Disease. Stage III disease according to the 1997 system.

486 views • 34 slides

The Role of Neoadjuvant Chemotherapy in Nonsmall Cell Lung Cancer

The Role of Neoadjuvant Chemotherapy in Nonsmall Cell Lung Cancer. Nil Molinas Mandel Istanbul University Cerrahpa?a Medical Faculty Medical Oncology Department. The use of systemic therapy before definitive local regional therapy is generally referred to as induction or neoadjuvant therapy.

909 views • 28 slides

Cancer Disparities Research Partnership (CDRP) Clinical Trials

649 views • 26 slides

Resectable disease Stage III Patients

NSCLC. Preoperative CT. Resectable disease Stage III Patients. Stage IIIA Preoperative CT Less competition but opportunity to take: NAVELBINE GEMZAR TAXOL TAXOTERE. NSCLC Main drugs. 91% (N 1 ) 87% (N 2 ). 78% (N 0 ) 76% (N 1 ). 100. 90. 66%. 62%. 80. 70. 39%. 60. 50.

256 views • 10 slides